Search

Author/Creator Eckert, Doerthe

1. A Population Pharmacokinetic Meta‐Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients. (19th June 2021)

Authors:
Stodtmann, Sven; Nuthalapati, Silpa; Eckert, Doerthe; Kasichayanula, Sreeneeranj; Joshi, Rujuta; Bach, Bruce A.; Mensing, Sven; Menon, Rajeev; Xiong, Hao
Journal:
Journal of clinical pharmacology
Issue:
Volume 61:Number 9(2021)
Page Start:
1195
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Exposure‐Response Model With Time‐Varying Predictors to Estimate the Effects of Veliparib in Combination With Carboplatin/Paclitaxel and as Monotherapy: Veliparib Phase 3 Study in BRCA‐Mutated Advanced Breast Cancer (BROCADE3) Trial. (5th May 2022)

Authors:
Stodtmann, Sven; Eckert, Doerthe; Joshi, Rujuta; Nuthalapati, Silpa; Ratajczak, Christine K.; Menon, Rajeev; Mensing, Sven; Xiong, Hao
Journal:
Journal of clinical pharmacology
Issue:
Volume 62:Number 10(2022)
Page Start:
1236
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Pharmacokinetics and Exposure–Efficacy Relationship of Adalimumab in Pediatric Patients with Moderate to Severe Crohn's Disease: Results from a Randomized, Multicenter, Phase-3 Study. Issue 4 (April 2015)

Authors:
Sharma, Shringi; Eckert, Doerthe; Hyams, Jeffrey S.; Mensing, Sven; Thakkar, Roopal B.; Robinson, Anne M.; Rosh, Joel R.; Ruemmele, Frank M.; Awni, Walid M.
Journal:
Inflammatory bowel diseases
Issue:
Volume 21:Issue 4(2015:Apr.)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis. (30th June 2019)

Authors:
Khatri, Amit; Eckert, Doerthe; Oberoi, Rajneet; Suleiman, Ahmed; Pang, Yinuo; Cheng, Ling; Othman, Ahmed A.
Journal:
Journal of clinical pharmacology
Issue:
Volume 59:Number 12(2019)
Page Start:
1656
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Population Pharmacokinetics of Glecaprevir/Pibrentasvir in HCV‐infected Japanese Subjects in Phase 3 CERTAIN‐1 and CERTAIN‐2 Trials. (12th September 2019)

Authors:
Suleiman, Ahmed Abbas; Lin, Chih‐Wei; Liu, Wei; Eckert, Doerthe; Mensing, Sven; Burroughs, Margaret; Kato, Koji; Chayama, Kazuaki; Kumada, Hiromitsu; Oberoi, Rajneet K.
Journal:
Journal of clinical pharmacology
Issue:
Volume 60:Number 3(2020)
Page Start:
331
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials. (3rd November 2016)

Authors:
Mensing, Sven; Eckert, Doerthe; Sharma, Shringi; Polepally, Akshanth R.; Khatri, Amit; Podsadecki, Thomas J.; Awni, Walid M.; Menon, Rajeev M.; Dutta, Sandeep
Journal:
British journal of clinical pharmacology
Issue:
Volume 83:Number 3(2017:Mar.)
Page Start:
527
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy. Issue 2 (9th February 2022)

Authors:
Brackman, Deanna; Eckert, Doerthe; Menon, Rajeev; Salem, Ahmed Hamed; Potluri, Jalaja; Smith, B. Douglas; Wei, Andrew H.; Hayslip, John; Miles, Dale; Mensing, Sven; Gopalakrishnan, Sathej; Zha, Jiuhong
Journal:
Hematological oncology
Issue:
Volume 40:Issue 2(2022)
Page Start:
269
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗